ABSTRACT
Endometrial adenocarcinoma is an important clinical problem of increasing incidence. This disease has superseded carcinoma of the cervix as the most common invasive gynecological malignancy in North America. The magnitude of the problem of drug resistant endometrial adenocarcinoma could be minimized if it were possible to decrease the incidence of the disease, achieve earlier diagnosis, and deliver optimal primary therapy. While the opportunities to prevent endometrial adenocarcinoma should not be exaggerated, neither should they be ignored. Evidence continues to accumulate which suggests increased levels of biologically active estrogen are a factor in the development of endometrial cancer. Tertiary preventative measures are synonymous with the components of optimal primary treatment. This designation emphasizes that the best opportunity for cure of endometrial cancer is with logically designed and carefully executed initial therapy, thus “preventing” avoidable recurrence. In spite of the relative frequency of advanced endometrial adenocarcinoma, little data regarding drug effectiveness exists.
